| Febuxostat (Teijin/Ipsen/TAP). | |
| | |
MedLine Citation:
|
PMID: 16312139 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Febuxostat (TEI-6720; TMX-67), an oral non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), is being developed by Teijin, with licensees Ipsen and TAP Holdings, for the potential treatment of gout. In February 2005, it was reported that launch in Japan was expected to be delayed for several years due to the need for additional clinical trials; in May 2005, an EU filing was expected by the end of 2005. |
| | |
Authors:
|
Brian Tomlinson |
Related Documents
:
|
22773769 - Effects of transdermal estrogen on collagen turnover at rest and in response to exercis... 22779909 - Novel mouth-exercising device for oral submucous fibrosis. 1950689 - Retrosigmoidal approach to the posterior cranial fossa. an anatomical study. 1554209 - Nasal cannula and transtracheal oxygen delivery. a comparison of patient response after... 18670989 - Aspergillosis and candidiasis in psittacine and passeriforme birds with particular refe... 10230529 - Aerodynamic, acoustic, and perceptual measures of nasality following traumatic brain in... 8761839 - Effects of 2,000 kcal per week of walking and stair climbing on physical fitness and ri... 23236449 - Transient increase in homocysteine but not hyperhomocysteinemia during acute exercise a... 10516539 - Perception of dyspnea during histamine- and methacholine-induced bronchoconstriction. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 6 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-11-29 Completed Date: 2006-06-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1168-78 Citation Subset: IM |
Affiliation:
|
Division of Clinical Pharmacology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China. btomlinson@cuhk.edu.hk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Drug Evaluation, Preclinical Enzyme Inhibitors / pharmacokinetics, pharmacology, therapeutic use* Gout / drug therapy* Humans Patents as Topic Randomized Controlled Trials as Topic Structure-Activity Relationship Thiazoles / pharmacokinetics, pharmacology, therapeutic use* Xanthine Oxidase / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Thiazoles; 144060-53-7/febuxostat; EC 1.17.3.2/Xanthine Oxidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney.
Next Document: Velafermin (CuraGen).